Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomoki Ito

Showing results (181-190 of 191) with videos related to

Pageof 20
Sort By:
Annals of Hematology|March 16, 2024
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective studyNaokazu Nakamura, Nobuyoshi Arima, Teruhito Takakuwa, et al.
Hematological Oncology|March 16, 2021
Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myelomaTeruhito Takakuwa, Kensuke Ohta, Eiji Nakatani, et al.
International Journal of Hematology|September 5, 2023
Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma ForumYuji Shimura, Hirohiko Shibayama, Aya Nakaya, et al.
International Journal of Hematology|September 22, 2020
Retrospective multi-center study of Adolescent and Young Adult (AYA) Multiple Myeloma in Kansai Myeloma Forum registryAya Nakaya, Takae Kohara, Hirohiko Shibayama, et al.
Scientific Reports|March 29, 2023
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulinYutaka Shimazu, Junya Kanda, Satoru Kosugi, et al.
International Journal of Hematology|February 20, 2026
Prospective observational study to assess the prognosis of patients with myeloproliferative neoplasms in Japan (MPN-15): results of baseline analysisKatsuto Takenaka, Tomoki Ito, Norio Komatsu, et al.
Therapeutic Advances in Hematology|December 19, 2022
Monocyte or white blood cell counts and β<sub>2</sub> microglobulin predict the durable efficacy of daratumumab with lenalidomideYutaka Shimazu, Junya Kanda, Hitomi Kaneko, et al.
Leukemia Research Reports|December 11, 2023
Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma ForumAya Nakaya, Hirohiko Shibayama, Nobuhiko Uoshima, et al.
Respiratory Investigation|December 7, 2024
Prevalence and causes of subacute cough in JapanYoshihisa Ishiura, Masaki Fujimura, Haruhiko Ogawa, et al.
Respiratory Investigation|March 24, 2024
Prevalence and causes of chronic cough in JapanYoshihisa Ishiura, Masaki Fujimura, Haruhiko Ogawa, et al.
Pageof 20

Showing results (181-190 of 191) with videos related to

Sort By:
Pageof 20
Annals of Hematology|March 16, 2024
Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective studyNaokazu Nakamura, Nobuyoshi Arima, Teruhito Takakuwa, et al.
Hematological Oncology|March 16, 2021
Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myelomaTeruhito Takakuwa, Kensuke Ohta, Eiji Nakatani, et al.
International Journal of Hematology|September 5, 2023
Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma ForumYuji Shimura, Hirohiko Shibayama, Aya Nakaya, et al.
International Journal of Hematology|September 22, 2020
Retrospective multi-center study of Adolescent and Young Adult (AYA) Multiple Myeloma in Kansai Myeloma Forum registryAya Nakaya, Takae Kohara, Hirohiko Shibayama, et al.
Scientific Reports|March 29, 2023
Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or B2 microglobulinYutaka Shimazu, Junya Kanda, Satoru Kosugi, et al.
International Journal of Hematology|February 20, 2026
Prospective observational study to assess the prognosis of patients with myeloproliferative neoplasms in Japan (MPN-15): results of baseline analysisKatsuto Takenaka, Tomoki Ito, Norio Komatsu, et al.
Therapeutic Advances in Hematology|December 19, 2022
Monocyte or white blood cell counts and β<sub>2</sub> microglobulin predict the durable efficacy of daratumumab with lenalidomideYutaka Shimazu, Junya Kanda, Hitomi Kaneko, et al.
Leukemia Research Reports|December 11, 2023
Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma ForumAya Nakaya, Hirohiko Shibayama, Nobuhiko Uoshima, et al.
Respiratory Investigation|December 7, 2024
Prevalence and causes of subacute cough in JapanYoshihisa Ishiura, Masaki Fujimura, Haruhiko Ogawa, et al.
Respiratory Investigation|March 24, 2024
Prevalence and causes of chronic cough in JapanYoshihisa Ishiura, Masaki Fujimura, Haruhiko Ogawa, et al.
Pageof 20